Výsledky vyhledávání - "David R. Wada"

Akademický článek

Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development

Autor: Yasong Lu, Shuang Liang, Ying Hong, Naoyuki Tajima, Kashyap Patel, Hanbin Li, David R. Wada, Jon Greenberg, Adam Petrich, Hong Zebger‐Gong, Dale Shuster, Pavan Vaddady

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 1, Pp 23-28 (2024)

Abstract To replace the conventional maximum tolerated dose (MTD) approach, a paradigm for dose optimization and dose selection that relies on model‐informed drug development (MIDD) approaches has been proposed in oncology. Here, we report our appl

Externí odkaz: https://doaj.org/article/07375fb147c347daba609e818c44fe7c

Zobrazit plný text záznamu

Plný text ve formátu HTML

Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes

Autor: Linh Nguyen, Dale Miles, Steve Milwee, David R. Wada, Yifah Yaron, Steven Lacy

Publikováno v: Cancer Chemotherapy and Pharmacology. 80:295-306

This study evaluated factors impacting QTc interval in a phase 3 trial of cabozantinib in progressive, metastatic, medullary thyroid cancer (MTC). Electrocardiogram (12-lead ECG) measurements were obtained at screening, and at pre-dose, and 2, 4, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5e908364c0e5f9df98e4f149e6570eb
https://doi.org/10.1007/s00280-017-3349-y

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání